



**Early Detection Town Hall Meeting
Webinar Program
9 July 2008**

Welcome

[June Kinoshita](#), Executive Editor, Alzheimer Research Forum

Introductory remarks

Harold Varmus, M.D., President and CEO, Memorial Sloan-Kettering Cancer Center

About the Alzheimer's Study Group

Rob Egge, Center for Health Transformation

The strategic importance and challenges of early detection of AD

[Sid Gilman](#), M.D., Director, Michigan Alzheimer's Disease Research Center

Early-stage and preclinical AD

[John Morris](#), M.D., Director, Alzheimer's Disease Research Center, Washington University St. Louis

Imaging biomarkers for early detection of AD

[Michael W. Weiner](#), M.D., Principal Investigator, Alzheimer's Disease Neuroimaging Initiative Director, Center for Imaging of Neurodegenerative Disease, VA Medical Center, San Francisco

Early detection of AD: fluid biomarkers

[Anne Fagan](#), Ph.D., Research Associate Professor of Neurology, Washington University, St. Louis

Translating early detection to the clinic

[Doug Galasko](#), M.D., Interim Director of UCSD Shiley-Marcos Alzheimer's Disease Research Center

The role of clinical and research Centers of Excellence in early diagnosis

[Rachelle Smith Doody](#), M.D., Ph.D., Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine

What pharma has/what pharma needs

[Richard Mohs](#), Ph.D., Leader, Alzheimer's Disease Team, Eli Lilly and Company

Early detection of AD: The patient's and caregiver's perspective

[Bill Bridgwater](#), patient advocate, National Board of Alzheimer's Association

Early detection and drug development: a brief overview

[Paul Aisen](#), M.D., University of California, San Diego (UCSD) School of Medicine's Department of Neurosciences, Director of the Alzheimer's Disease Cooperative Study (ADCS)